REPARE THERAPEUTICS INC (RPTX)
US7602731025 - Common Stock
We assign a fundamental rating of 3 out of 10 to RPTX. RPTX was compared to 564 industry peers in the Biotechnology industry. RPTX has a great financial health rating, but its profitability evaluates not so good. RPTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RPTX had negative earnings in the past year.
In the past year RPTX has reported a negative cash flow from operations.
RPTX had negative earnings in each of the past 5 years.
RPTX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of RPTX (-36.92%) is better than 60.61% of its industry peers.
The Return On Equity of RPTX (-44.20%) is better than 70.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.92% | ||
| ROE | -44.2% | ||
| ROIC | N/A |
ROA(3y)-24.63%
ROA(5y)-23.07%
ROE(3y)-30.56%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RPTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RPTX has been increased compared to 1 year ago.
Compared to 5 years ago, RPTX has more shares outstanding
RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 0.00, we must say that RPTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.00, RPTX is in the better half of the industry, outperforming 61.32% of the companies in the same industry.
RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0 |
ROIC/WACCN/A
WACC9.37%
2.3 Liquidity
A Current Ratio of 6.24 indicates that RPTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.24, RPTX is doing good in the industry, outperforming 62.21% of the companies in the same industry.
RPTX has a Quick Ratio of 6.24. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
RPTX's Quick ratio of 6.24 is fine compared to the rest of the industry. RPTX outperforms 62.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.24 | ||
| Quick Ratio | 6.24 |
3. Growth
3.1 Past
The earnings per share for RPTX have decreased strongly by -993.33% in the last year.
The Revenue for RPTX has decreased by -61.20% in the past year. This is quite bad
RPTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 699.65% yearly.
EPS 1Y (TTM)-993.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-192.86%
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5YN/A
Sales Q2Q%-96.45%
3.2 Future
RPTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.36% yearly.
The Revenue is expected to grow by 20.56% on average over the next years. This is a very strong growth
EPS Next Y-1.42%
EPS Next 2Y-20.56%
EPS Next 3Y-8.31%
EPS Next 5Y13.36%
Revenue Next Year-4.4%
Revenue Next 2Y-60.29%
Revenue Next 3Y-13.14%
Revenue Next 5Y20.56%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as RPTX's earnings are expected to decrease with -8.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.56%
EPS Next 3Y-8.31%
5. Dividend
5.1 Amount
RPTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPARE THERAPEUTICS INC
NASDAQ:RPTX (11/4/2024, 8:00:02 PM)
After market: 3.62 +0.04 (+1.12%)3.58
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap151.97M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.92% | ||
| ROE | -44.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.24 | ||
| Quick Ratio | 6.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-993.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-1.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y